Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates

mAbs

Volumn 8, Issue 3, 2016, Pages 513-523

  Catcott, Kalli C ^a   McShea, Molly A ^a   Bialucha, Carl Uli ^b   Miller, Kathy L ^b   Hicks, Stuart W ^a   Saxena, Parmita ^b   Gesner, Thomas G ^b   Woldegiorgis, Mikias ^b   Lewis, Megan E ^a   Bai, Chen ^a   Fleming, Michael S ^a   Ettenberg, Seth A ^b,c   Erickson, Hans K ^a,d   Yoder, Nicholas C ^a  

^a IMMUNOGEN INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Unum Therapeutics   (United States)

^d GENENTECH INC   (United States)

Author keywords

Antibody; antibody drug conjugate; conjugation; high throughput; maytansinoid; protein chemistry

Indexed keywords

ANTIBODY CONJUGATE; CANCER ANTIBODY; MAYTANSINE; MONOCLONAL ANTIBODY;

ANTIBODY SCREENING; ANTIGEN PURIFICATION; AREA UNDER THE CURVE; ARTICLE; CONJUGATION; CYTOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; IC50; DRUG SCREENING; HUMAN; IMMUNOLOGY; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; NEOPLASMS;

EID: 84961613545     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1134408     Document Type: Article

References (44)

1. R.V.Chari, M.L.Miller, W.C.Widdison. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014; 53:3796-827; PMID:24677743; http://dx.doi.org/10.1002/anie.201307628
2. E.L.Sievers, P.D.Senter. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64:15-29; PMID:23043493; http://dx.doi.org/10.1146/annurev-med-050311-201823
3. B.A.Teicher, J.H.Doroshow. The promise of antibody-drug conjugates. N Engl J Med 2012; 367:1847-8; PMID:23134386; http://dx.doi.org/10.1056/NEJMe1211736
4. S.Verma, D.Miles, L.Gianni, I.E.Krop, M.Welslau, J.Baselga, M.Pegram, D.Y.Oh, V.Dieras, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367:1783-91; PMID:23020162; http://dx.doi.org/10.1056/NEJMoa1209124
5. A.Younes, A.K.Gopal, S.E.Smith, S.M.Ansell, J.D.Rosenblatt, K.J.Savage, R.Ramchandren, N.L.Bartlett, B.D.Cheson, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30:2183-9; PMID:22454421; http://dx.doi.org/10.1200/JCO.2011.38.0410
6. R.V.Chari. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008; 41:98-107; PMID:17705444; http://dx.doi.org/10.1021/ar700108g
7. W.C.Widdison, S.D.Wilhelm, E.E.Cavanagh, K.R.Whiteman, B.A.Leece, Y.Kovtun, V.S.Goldmacher, H.Xie, R.M.Steeves, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006; 49:4392-408; PMID:16821799; http://dx.doi.org/10.1021/jm060319f
8. R.Singh, H.K.Erickson. Antibody-cytotoxic agent conjugates: preparation and characterization. Methods Mol Biol 2009; 525:445-67, xiv; PMID:19252846; http://dx.doi.org/10.1007/978-1-59745-554-1_23
9. H.H.Shih Discovery Process for Antibody-Based Therapeutics. In: M.A.Tabrizi, G.G.Bornstein, S.L.Klakamp, editors. Development of Antibody-Based Therapeutics. New York: Springer. 2012 pp. Nine-32.
10. A.G.Polson, M.Williams, A.M.Gray, R.N.Fuji, K.A.Poon, J.McBride, H.Raab, T.Januario, M.Go, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010; 24:1566-73; PMID:20596033; http://dx.doi.org/10.1038/leu.2010.141
11. J.Baselga, K.A.Gelmon, S.Verma, A.Wardley, P.Conte, D.Miles, G.Bianchi, J.Cortes, V.A.McNally, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-44; PMID:20124182; http://dx.doi.org/10.1200/JCO.2009.24.2024
12. T.Ben-Kasus, B.Schechter, S.Lavi, Y.Yarden, M.Sela. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 2009; 106:3294-9; PMID:19218427; http://dx.doi.org/10.1073/pnas.0812059106
13. K.Koefoed, L.Steinaa, J.N.Soderberg, I.Kjaer, H.J.Jacobsen, P.J.Meijer, J.S.Haurum, A.Jensen, M.Kragh, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011; 3:584-95; PMID:22123060; http://dx.doi.org/10.4161/mabs.3.6.17955
14. S.C.Owen, N.Patel, J.Logie, G.Pan, H.Persson, J.Moffat, S.S.Sidhu, M.S.Shoichet. Targeting HER2+ breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. J Control Release 2013; 172(2):395-404; PMID:23880472; http://dx.doi.org/10.1016/j.jconrel.2013.07.011
15. Y.Zhou, J.D.Marks. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol 2012; 502:43-66; PMID:22208981; http://dx.doi.org/10.1016/B978-0-12-416039-2.00003-3
16. B.Krebs, R.Rauchenberger, S.Reiffert, C.Rothe, M.Tesar, E.Thomassen, M.Cao, T.Dreier, D.Fischer, et al. High-throughput generation and engineering of recombinant human antibodies. J Immunol Methods 2001; 254:67-84; PMID:11406154; http://dx.doi.org/10.1016/S0022-1759(01)00398-2
17. J.E.Stefano, M.Busch, L.Hou, A.Park, D.A.Gianolio. Micro- and mid-scale maleimide-based conjugation of cytotoxic drugs to antibody hinge region thiols for tumor targeting. Methods Mol Biol 2013; 1045:145-71; PMID:23913146; http://dx.doi.org/10.1007/978-1-62703-541-5_9
18. C.Kellner, W.K.Bleeker, J.J.Lammerts van Bueren, M.Staudinger, K.Klausz, S.Derer, P.Glorius, A.Muskulus, B.E.de Goeij, et al. Human kappa light chain targeted Pseudomonas exotoxin A–identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. J Immunol Methods 2011; 371:122-33; PMID:21756911; http://dx.doi.org/10.1016/j.jim.2011.06.023
19. A.Wakankar, Y.Chen, Y.Gokarn, F.S.Jacobson. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011; 3:161-72; PMID:21441786; http://dx.doi.org/10.4161/mabs.3.2.14960
20. G.T.Hermanson Bioconjugate Techniques, 2nd edition. London: Academic Press 2008.
21. J.M.Bland, D.G.Altman. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-10; PMID:2868172; http://dx.doi.org/10.1016/S0140-6736(86)90837-8
22. D.Sun, A.Whitty, J.Papadatos, M.Newman, J.Donnelly, S.Bowes, S.Josiah. Adopting a practical statistical approach for evaluating assay agreement in drug discovery. J Biomol Screen 2005; 10:508-16; PMID:16093560; http://dx.doi.org/10.1177/1087057105275725
23. M.Trneny, G.Verhoef, M.J.S.Dyer, D.B.Yehuda, C.Patti, M.Canales, A.Lopez, F.Awan, P.Montgomery, et al. Starlyte Phase II study of Coltuximab Ravtansine (CoR, SAR3419) Single Agent: Clinical Activity and Safety in Patients with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL; NCT01472887). American Society for Clinical Oncology presentation. 2014. abstr. #8506.
24. D.Lowe, K.Dudgeon, R.Rouet, P.Schofield, L.Jermutus, D.Christ. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61; PMID:21846562; http://dx.doi.org/10.1016/B978-0-12-386483-3.00004-5
25. R.P.Lyon, D.R.Benjamin, M.C.Ryan Methods for Screening Antibodies. WO2011109308 A1. WIPO Patent Application. 2011 pp. PCT/US2011/026534.
26. R.P.Lyon, M.C.Ryan, H.Kostner, E.B.Meyer, M.S.Sutherland, C.Yu, K.A.Gordon, D.R.Benjamin. Development of Parallel Conjugation and Assay Methodologies to Screen for Antibodies with Optimal Properties for use as Antibody-Drug Conjugates; 2010; Washington, DC abstr. #4394.
27. E.S.Zimmerman, T.H.Heibeck, A.Gill, X.Li, C.J.Murray, M.R.Madlansacay, C.Tran, N.T.Uter, G.Yin, et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem 2014; 25:351-61; PMID:24437342; http://dx.doi.org/10.1021/bc400490z
28. S.Michael, D.Auld, C.Klumpp, A.Jadhav, W.Zheng, N.Thorne, C.P.Austin, J.Inglese, A.Simeonov. A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 2008; 6:637-57; PMID:19035846; http://dx.doi.org/10.1089/adt.2008.150
29. N.Stephanopoulos, M.B.Francis. Choosing an effective protein bioconjugation strategy. Nat Chem Biol 2011; 7:876-84; PMID:22086289; http://dx.doi.org/10.1038/nchembio.720
30. C.D.Spicer, B.G.Davis. Selective chemical protein modification. Nat Commun 2014; 5:4740; PMID:25190082; http://dx.doi.org/10.1038/ncomms5740
31. R.K.McGinty, J.Kim, C.Chatterjee, R.G.Roeder, T.W.Muir. Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation. Nature 2008; 453:812-6; PMID:18449190; http://dx.doi.org/10.1038/nature06906
32. M.W.Popp, S.K.Dougan, T.Y.Chuang, E.Spooner, H.L.Ploegh. Sortase-catalyzed transformations that improve the properties of cytokines. Proc Natl Acad Sci U S A 2011; 108:3169-74; PMID:21297034; http://dx.doi.org/10.1073/pnas.1016863108
33. X.Li, T.Fang, G.J.Boons. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew Chem Int Ed Engl 2014; 53:7179-82; PMID:24862406; http://dx.doi.org/10.1002/anie.201402606
34. P.M.Drake, A.E.Albers, J.Baker, S.Banas, R.M.Barfield, A.S.Bhat, G.W.de Hart, A.W.Garofalo, P.Holder, et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 2014; 25:1331-41; PMID:24924618; http://dx.doi.org/10.1021/bc500189z
35. C.Jost, A.Pluckthun. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr Opin Struct Biol 2014; 27C:102-12; PMID:25033247; http://dx.doi.org/10.1016/j.sbi.2014.05.011
36. H.Byrne, P.J.Conroy, J.C.Whisstock, R.J.O'Kennedy. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
37. J.Anderl, H.Faulstich, T.Hechler, M.Kulke. Antibody-drug conjugate payloads. Methods Mol Biol 2013; 1045:51-70; PMID:23913141; http://dx.doi.org/10.1007/978-1-62703-541-5_4.
38. A.Dirksen, M.Madsen, G.Dello Iacono, M.J.Matin, M.Bacica, N.Stankovic, S.Callans, A.Bhat. Parallel synthesis and screening of peptide conjugates. Bioconjug Chem 2014; 25:1052-60; PMID:24824568; http://dx.doi.org/10.1021/bc500129w
39. J.Yang, H.Chen, I.R.Vlahov, J.X.Cheng, P.S.Low. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci U S A 2006; 103:13872-7; PMID:16950881; http://dx.doi.org/10.1073/pnas.0601455103
40. H.Zhao, O.Graf, N.Milovic, X.Luan, M.Bluemel, M.Smolny, K.Forrer. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J Pharm Sci 2010; 99:2279-94; PMID:20014026; http://dx.doi.org/10.1002/jps.22008
41. H.S.Samra, F.He. Advancements in high throughput biophysical technologies: applications for characterization and screening during early formulation development of monoclonal antibodies. Mol Pharm 2012; 9:696-707; PMID:22263524; http://dx.doi.org/10.1021/mp200404c
42. C.Liu, B.M.Tadayoni, L.A.Bourret, K.M.Mattocks, S.M.Derr, W.C.Widdison, N.L.Kedersha, P.D.Ariniello, V.S.Goldmacher, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996; 93:8618-23; PMID:8710920;.
43. K.R.Whiteman, H.A.Johnson, M.F.Mayo, C.A.Audette, C.N.Carrigan, A.LaBelle, L.Zukerberg, J.M.Lambert, R.J.Lutz. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs 2014; 6:556-66; PMID:24492307; http://dx.doi.org/10.4161/mabs.27756
44. M.S.Fleming, W.Zhang, J.M.Lambert, G.Amphlett. A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. Anal Biochem 2005; 340:272-8; PMID:15840500; http://dx.doi.org/10.1016/j.ab.2005.02.010